Heartseed is a biotech company developing iPSC-derived purified cardiomyocytes for heart failure. Founded by Professor Keiichi Fukuda, the world leading physician scientist in the field of cardiac regenerative medicine, Heartseed has raised $40MM since its foundation in 2015 including the recent Series B in 2019.
The company's lead pipeline, HS-001 can be safely transplanted into patient's myocardium because of is >99% purity achieved by our proprietary metabolic selection technologies. Compared with previous cell therapy products, higher response rate and higher efficacy in cardiac functional improvement are expected as HS-001 grow and electrically synchronized with other cells within the myocardium.
First-in-Human trial of HS-001 was approved by Keio University Review Committee in early 2020 and will be initiated in late 2020. Company-sponsored Ph1/2 trial will also be initiated in 2021.
Out-licensing discussion is ongoing for ex-Japan market.
The company's lead pipeline, HS-001 can be safely transplanted into patient's myocardium because of is >99% purity achieved by our proprietary metabolic selection technologies. Compared with previous cell therapy products, higher response rate and higher efficacy in cardiac functional improvement are expected as HS-001 grow and electrically synchronized with other cells within the myocardium.
First-in-Human trial of HS-001 was approved by Keio University Review Committee in early 2020 and will be initiated in late 2020. Company-sponsored Ph1/2 trial will also be initiated in 2021.
Out-licensing discussion is ongoing for ex-Japan market.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2015
Main Therapeutic Focus:
Cardiovascular
Lead Product in Development:
HS-001, allogeneic iPSC-derived cardiomyocyte spheroids
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
